心不全患者の運動中の過度の腎血管収縮
H R Middlekauff1, E U Nitzsche, C K Hoh
1Division of Cardiology, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Circulation
|February 23, 2000
まとめ
心不全の患者は,運動中に過度の腎血管収縮を示し,健康な人よりも長く持続します. この反応に対する筋肉メタボレセプターの貢献は,心不全では減少する.
科学分野:
- 心血管生理学 心血管生理学
- 腎臓生理学 腎臓生理学
- 運動生理学 運動生理学
背景:
- 健康なヒトは静的運動中に反射性腎皮質血管収縮を呈する.
- 筋肉のメタボレセプターは,この運動誘発性腎血管収縮に大きく寄与する.
- 心不全患者の運動に対する腎血管調子の反応は不明である.
研究 の 目的:
- 心不全患者の運動中の反射性腎血管収縮を調査する.
- 運動中に心不全患者と健康な対照群の腎血管応答を比較するために.
- 心不全における腎血管収縮における筋肉代謝受容体の役割を明らかにする.
主な方法:
- 39人の心不全患者 (NYHAクラスIII-IV) と38人の対照群は,腎臓の血流量測定のためのダイナミック・ポジトロン放出トモグラフィーを受けた.
- 段階的な握手運動と握手後の不血性停止は,反射メカニズムを評価するために使用されました.
- 腎臓の血管収縮は,持続的な握手および循環停止の間に量化され,筋肉のメタボレセプターに影響を隔離しました.
主要な成果:
- 心不全の患者は,コントロール群と比較して,持続的な握手中にピーク腎血管収縮が有意に大きく示された (70+/-13 vs. 42+/-1 U,P=0.02).
- 腎血管収縮は,対照群と比較して,心不全患者でより長く持続しました (2-5分で増加) (ベースラインに戻りました).
- ハンドグリップ後の循環停止の間,心不全患者 (20+/-5 vs. 30+/-2 U,P=0.05) で腎血管収縮が鈍化しており,筋肉代謝受容体貢献が低下していることを示しています.
結論:
- 心不全患者の持続的な運動中に反射性腎血管収縮の大きさと持続時間は誇張されています.
- 筋肉のメタボレセプターは,心不全患者のリフレックス腎血管収縮を介し,健康な個人に比べて鈍化した役割を果たしています.
関連する概念動画
Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Exercise and Cardiovascular Response
6.7K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.7K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632


